Edition:
United States

Albany Molecular Research Inc (AMRI.OQ)

AMRI.OQ on NASDAQ Stock Exchange Global Select Market

13.06USD
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
$13.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
91,153
52-wk High
$19.35
52-wk Low
$12.46

Latest Key Developments (Source: Significant Developments)

Albany Molecular Research files for secondary offering of 2.2 mln shares
Friday, 17 Mar 2017 12:06pm EDT 

Albany Molecular Research Inc :Files to say selling stockholders may offer and sell up to 2.2 million shares of co's common stock - SEC filing.  Full Article

Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare
Tuesday, 21 Feb 2017 08:05am EST 

Albany Molecular Research Inc : Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc. . Albany Molecular - agreement to develop, manufacture undisclosed complex parenteral drug product for registration, subsequent commercialization in u.s. . Albany molecular - under terms, amri to work with ferrer to develop, initially provide cgmp manufacturing, analytical support for registration of new product .Albany molecular research inc - accord healthcare to be responsible for advancing product candidate through regulatory submission, commercialization.  Full Article

AMRI posts Q4 adj. earnings per share $0.34
Tuesday, 21 Feb 2017 07:28am EST 

Albany Molecular Research Inc : AMRI announces fourth quarter and full year 2016 results and provides 2017 outlook . Q4 non-GAAP earnings per share $0.34 . Q4 loss per share $0.37 . Q4 revenue rose 51 percent to $191.3 million . Q4 earnings per share view $0.48 -- Thomson Reuters I/B/E/S . Sees 2017 non-GAAP diluted EPS $1.08 to $1.20 . Sees 2017 GAAP diluted loss per share $0.28 to $0.16 . FY2017 earnings per share view $1.30, revenue view $763.3 million -- Thomson Reuters I/B/E/S . Albany Molecular Research Inc - sees 2017 capital expenditures $35 million to $40 million .Albany Molecular Research Inc sees 2017 revenue $710 million to $740 million.  Full Article

Amri Q3 non-gaap EPS $0.17
Tuesday, 8 Nov 2016 07:30am EST 

Albany Molecular Research Inc : Reaffirms 2016 outlook . Albany molecular research inc sees full year 2016 capital expenditures of approximately $48 million . Fy2016 earnings per share view $1.08 -- Thomson Reuters I/B/E/S . Amri announces third quarter 2016 results . Q3 non-gaap earnings per share $0.17 . Q3 loss per share $0.57 . Q3 revenue rose 46 percent to $152.7 million . Q3 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees fy 2016 non-gaap earnings per share $1.03 to $1.11 .Sees fy 2016 revenue $590 million to $615 million.  Full Article

Albany Molecular files for secondary offering of 7 million shares of its common stock
Friday, 23 Sep 2016 04:32pm EDT 

Albany Molecular Research Inc :Albany Molecular files for secondary offering of 7 million shares of its common stock - SEC filing.  Full Article

Albany Molecular Research announces restructuring plan of certain operations in U.S.and Europe
Monday, 29 Aug 2016 05:19pm EDT 

Albany Molecular Research Inc : Announced a restructuring plan with respect to certain operations in United States and Europe . Restructuring plan in connection with previously announced acquisition of prime European therapeuticals S.P.A Euticals . Under plan, co expects to incur certain charges related to reduction in force, other transition activities between $5.7 - $7.3 million . Cash charges will consist of $5.5 - $7.1 million of employee and other related costs and will primarily be paid during second half of 2016 .Company expects majority of these charges to be recorded in second half of 2016..  Full Article

Albany Molecular Research reports Q2 loss per share $0.61
Thursday, 4 Aug 2016 07:30am EDT 

Albany Molecular Research Inc : Amri announces second quarter 2016 results . Q2 revenue rose 35 percent to $120.8 million . Q2 loss per share $0.61 . Q2 non-GAAP earnings per share $0.36 . Q2 earnings per share view $0.32 -- Thomson Reuters I/B/E/S . Sees FY 2016 revenue $590 million to $615 million . Sees FY 2016 non-GAAP earnings per share $1.03 to $1.11 .Sees 2016 capital expenditures of approximately $48 million.  Full Article

Albany Molecular Research clarifies 2016 revenue guidance
Tuesday, 10 May 2016 11:34am EDT 

: AMRI clarifies 2016 revenue guidance . Company expects approximately 50% of its 2016 revenue to be realized in first half of year .Continues to expect about 40% of 2016 adjusted eps to be realized in H1,corresponding 60% in second half of year, respectively.  Full Article

AMRI posts Q1 loss of $0.29/share
Tuesday, 10 May 2016 08:00am EDT 

Albany Molecular Research Inc : AMRI announces first quarter 2016 results . Q1 GAAP loss per share $0.29 . Q1 adjusted non-GAAP earnings per share $0.07 . Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S . Q1 revenue rose 29 percent to $105.6 million . Sees FY 2016 revenue up 19 percent . Sees FY 2016 revenue $465 million to $490 million . FY adjusted diluted EPS is expected to be between $1.00 and $1.10 . Fy2016 earnings per share view $1.05, revenue view $479.2 million -- Thomson Reuters I/B/E/S . Confirms standalone full year 2016 financial guidance . Q1 contract revenue of $102.8 million, up 37% from 2015 .Sees 2016 capital expenditures of approximately $45 million.  Full Article

Albany Molecular Research Inc gives FY 2016 guidance
Wednesday, 17 Feb 2016 07:31am EST 

Albany Molecular Research Inc:Expects FY 2016 revenue to be between $465 to $490 million.Expects FY 2016 adjusted EPS to be between $1.00 and $1.10 per diluted share.  Full Article

More From Around the Web

BRIEF-Albany Molecular Research enters into agreement with pharmaceutical group Ferrer, Accord Healthcare

* Albany Molecular Research Inc - entered into an agreement with pharmaceutical group Ferrer and Accord Healthcare, Inc.